期刊文献+

甲状腺功能亢进症患者血浆Ghrelin水平的改变及其影响因素探讨 被引量:8

Changes of plasma ghrelin levels and relevant factors in hyperthyroidism patients
下载PDF
导出
摘要 目的了解甲状腺功能亢进症患者血浆生长激素促分泌素受体的内源性配体Ghrelin水平的改变及抗甲状腺药物治疗对血浆Ghrelin水平的影响。方法采用酶联免疫法测定正常成人和初发甲亢患者治疗前后血浆Ghrelin水平,分析血浆Ghrelin与FT3、FT4、S-TSH、体质量指数、体脂百分比、空腹血糖的关系。结果甲亢患者血浆Ghrelin水平较对照组明显降低[分别为(468±136)、(751±212)ng/L,P<0.01]。经他巴唑治疗1个月后血浆Ghrelin水平、体质量及BMI升高(P<0.01),他巴唑治疗2个月后血浆Ghrelin水平与正常对照组比较无明显差异[分别为(670±214)、(751±212)ng/L,P>0.05]。相关性分析表明血浆Ghrelin水平与FT4、FT3浓度呈明显负相关(r=-0.43,r=-0.37,P<0.01),而与S-TSH和体脂百分比呈明显正相关(r=0.29,P<0.01;r=0.26,P<0.05)。多元线性逐步回归分析提示FT4是影响血浆Ghrelin水平的独立相关因素。结论甲亢患者血浆Ghrelin水平的显著降低可能与甲亢患者高水平的甲状腺激素抑制了Ghrelin的分泌有关。 Objective To investigate plasma ghrelin levels in the patients with hyperthyroidism and their relation to thyroid hormones. Methods Plasma ghrelin levels were assayed by ELISA in 20 normal subjects and 26 hyperthyroidism patients before and after medical treatment. The relationship between plasma ghrelin levels and thyroid hormones was also analyzed. Results Plasma ghrelin levels were significantly lower in the hyperthyroidism patients than the controls [ (468 ± 136) ng/L vs (751 ±212) ng/L, P 〈0.01 ]. After Methimazole treatment for 1 month, plasma ghrelin levels, body weight and Body Mass Index (BMI) were significantly increased in hyperthyroidism patients in comparison with the controls [ (468 ± 136) ng/L vs (563 ± 194) rig/L, (51.1 ±8.3) kgvs (54.2 ±8.1) kg, (19.8 ±2.4) kg/m^2 vs (20.6 ±2.2) kg,/m^2, P〈0.01]. Two months later, plasma ghrelin levels in patients treated with Methimazole were similar to the controls I (670 ± 214) ng/L vs (751 ±212) ng/L, P 〉0.05 ]. Plasma ghrelin levels were correlated negatively with FT4 and FT3 (r= -0.43, and r = -0.37, both P〈0.01), and positively with S-TSH and FAT% (r=0.29, P 〈0.01 ; r =0.26, P 〈0.05 ). Multiple regression analysis showed that FT4 was independent factor related to plasma Ghrelin levels. Conclusion The circulating levels of plasma ghrelin are reduced in the patients with hyperthyroidism, but they recover after treatment. The ghrelin secretion may be suppressed by increasing thyroid hormones.
出处 《第三军医大学学报》 CAS CSCD 北大核心 2008年第4期358-360,共3页 Journal of Third Military Medical University
关键词 GHRELIN 甲状腺功能亢进症 甲状腺激素 ghrelin hyperthyroidism thyroid hormones
  • 相关文献

参考文献12

  • 1Kojima M, Hosoda H, Date Y, et al. Ghrelin is a growth-hormonereleasing acylated peptide from stomach [ J ]. Nature, 1999, 402 (6762) : 656 - 660.
  • 2Shintani M, Ogawa Y, Ebihara K, et al. Ghrelin, an endogenous growth hormone secretagogue, is a novel orexigenic peptide that antagonizes leptin action through the activation of hypothalamic neuropeptide Y/Y1 receptor pathway [J]. Diabetes, 2001, 50(2): 227-232.
  • 3Chen H Y, Trumbauer M E, Chen A S, et al. Orexigenic action of peripheral ghrelin is mediated by neuropeptide Y and agouti-related protein[J]. Endocrinology, 2004, 145(6) : 2607 - 2612.
  • 4Cummings D E, Pumell J Q, Frayo R S, et al. A preprandial rise in plasma ghrelin levels suggests a role in meal initiation in humans [ J ]. Diabetes, 2001, 50(8) : 1714 - 1719.
  • 5le-Roux C W, Patterson M, Vincent R P, et al. Postprandial plasma ghrelin is suppressed proportional to meal calorie content in normalweight but not obese subjects[J]. J Clin Endocrinol Metab, 2005,90 (2) : 1068 - 1071.
  • 6Tschop M, Weyer C, Tataranni P A, et al. Circulating ghrelin levels are decreased in human obesity[J]. Diabetes, 2001, 50(4) : 707 -709.
  • 7Hansen T K, Dall R, Hosoda H, et al. Weight loss increases circulating levels of ghrelin in human obesity [ J ]. Clin Endocrinol (Oxf) , 2002, 56(2) : 203 -206.
  • 8Sofiano-Guillen L, Barrios V, Campos-Barros A, et al. Ghrelin levels in obesity and anorexia nervosa: effect of weight reduction or recuperation[J]. JPediatr, 2004, 144(1): 36-42.
  • 9Otto B, Cuntz U, Fruehauf E, et al. Weight gain decreases elevated plasma ghrelin concentrations of patients with anorexia nervosa [ J ]. Eur J Endocrinol, 2001, 145 (5) : 669 -673.
  • 10Nagaya N, Uematsu M, Kojima M, et al. Elevated circulating level of ghrelin in cachexia associated with chronic heart failure: relationships between ghrelin and anabolic/catabolic factors [ J ]. Circulation, 2001, 104(17) : 2034 -2038.

二级参考文献8

  • 1顾卫琼,中华内分泌代谢杂志,1999年,15卷,15页
  • 2Montague C T,Diabetes,1997年,46卷,342页
  • 3Sih R,J Clin Endoc Metab,1997年,82卷,1661页
  • 4Kopp W,Mol Psychiatry,1997年,2卷,335页
  • 5Sainsbury A,Diabetologia,1996年,39卷,353页
  • 6Considine R V,New Engl J Med,1996年,334卷,292页
  • 7Zhang Y,Nature,1994年,372卷,425页
  • 8顾卫琼,陈名道,唐金凤,李凤英,陈春荣,罗敏,陈家伦,许曼音.中国人血清瘦素水平与肥胖度的关系[J].中华内分泌代谢杂志,1999,15(1):15-18. 被引量:193

共引文献26

同被引文献71

  • 1陈煜辉,周莺.柴胡疏肝散抗抑郁作用的药理学实验研究[J].江西中医学院学报,2004,16(4):59-60. 被引量:57
  • 2孙桂荣,田字彬,綦玉琴,李雨生,于素清,余云云.甲状腺功能与血清ghrelin和胖素-A水平的相关性[J].中华内科杂志,2005,44(3):217-218. 被引量:3
  • 3张玉芳,王海宁,洪天配.ghrelin在甲状腺疾病组织中的表达[J].北京大学学报(医学版),2006,38(2):193-196. 被引量:6
  • 4罗清礼,何为民,夏庆杰,曹桂群,闫乃红,王玲,张发强.甲状腺相关眼病患者眼眶组织糖皮质激素受体mRNA的表达[J].中华眼科杂志,2007,43(1):40-43. 被引量:12
  • 5杨华胜 吴中耀.甲状腺相关眼病[M].吴中耀主编.现代眼肿瘤眼眶[C].北京:人民卫生出版社,2002.464-497.
  • 6Kojima M,Hosoda H,Date Y,et al.Ghrelin is a growth-hormone releasingacylated peptide from stomach[J].Nature,1999,402(9):656-660.
  • 7Kmegai J,Tamura H,Shimizu T,et al.The role of pituitary ghrelin in growth hormone(GH)secretion:GH-releasing hormone dependent regulation of puitary ghrelin gene expression and peptide content[J].Endocrinology,2004,145(8):3731-3738.
  • 8Gimeˊnez-Palop O,Gimeˊnez-Peˊrez G,Mauricio D,et al.Circulating ghrelin in thyroid dysfunction is related to insulin resistance and not to hunger,food intake or anthropometric changes[J].Eur J Endocrinol,2005,153(1):73-79.
  • 9Sadegholvad MD,Mfkhamizadeh MD,Ranjbar-Omrani MD.Serum ghrelin changes in thyroid dysfunction[J].Arch Iranian Med,2007,10(2):168-170.
  • 10Juhasz A,Katona E,Csongradi E,et al.The regulation of body mass and its relation to the development of obesity[J].Orv Hetil,2007,148(39):1827-1836.

引证文献8

二级引证文献22

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部